Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data

Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate 2015. doi: 10.1002/pros.23099. [Epub ahead of print]

Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration

Agur Z., Elishmereni M., Kheifetz Y. , Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley interdisciplinary reviews. Systems biology and medicine 6, 239-253 (2014)

Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.
Vainas O. et el.
Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. British Journal of Cancer 814–822 (2012).doi:10.1038/bjc.2012.316
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization

Jager E., van der Velden V.H., Te Marvelde JG., Walter R.B., Agur Z., Vainstein V.
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS one 2011 6(9) e24265

From the Evolution of Toxin Resistance to Virtual Clinical Trials – the Role of Mathematical Models in Oncology

Agur Z.
From the Evolution of Toxin Resistance to Virtual Clinical Trials – the Role of Mathematical Models in Oncology, Future Oncology, 2010;6(6), (pp. 917-27).
 

Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model

Gorelik B., Ziv I., Shohat R., Wick M., Hankins D., Sidransky D., Agur Z.
Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008;68(21), (pp. 9033–9040).

Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study

Agur Z., Elishmereni M., Kogan Y., Kheiffetz Y., Ziv I., Shoham M., and Vainstein V. "Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study" in 'Preclinical Development Handbook', Shayne Gad Ed., John Wiley & Sons, USA. 2008, pp 1229-1266.

Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor: Insights from a Computerized Model of Human Granulopoiesis

Vainstein V., Ginosar Y., Shoham M., Ianovski A., Rabinovich A., Kogan Y., Selitser V., and Agur Z.
Improving cancer therapy by Doxorubicin and Granulocyte colony-stimulating factor: insights from a computerized model of human Granulopoiesis, Math .Model. Nat. Phenom. Vol. 1, No. 2, 2006 (pp. 70-80).

Optimizing chemotherapy scheduling using local search heuristics

Agur Z., Hassin R., Levy S.
Optimizing chemotherapy scheduling using local search heuristics, Operations Research. 2006 Sep;54 (5) 2006 (pp.829-846).

Biomathematics in the development of personalized medicine in oncology

Agur Z.
Biomathematics in the development of personalized medicine in oncology. Future Oncol. 2006 Feb;2 (1):39-42.

The Cross-Entropy Method for Continuous Multi-Extremal Optimization
Kroese D., P., Porotsky S., Rubinstein R., Y.
The Cross-Entropy Method for Continuous Multi-Extremal Optimization. Methodol. Comput. Appl. Probab. Vol. 8 No. 3, 2006 (p.383–407)